Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Open Label, Multiple Dose, Dose Escalation and Cohort Expansion Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

NCT04257110 is registered in ClinicalTrials.gov with Bliss Biopharmaceutical (Hangzhou) Co., Ltd as lead sponsor.

NCT NCT04257110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04257110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Open Label, Multiple Dose, Dose Escalation and Cohort Expansion Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors
Lead sponsor
Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
July 28, 2020
Completion date
December 31, 2024
Enrollment
117 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced/metastatic her2 positive solid tumors